NuCana (NCNA) Net Equity Issued and Repurchased (2018 - 2025)
NuCana (NCNA) reported Net Equity Issued and Repurchased of $25.6 million for Q3 2025, up 303.64% on a YoY basis from $6.3 million in Q3 2024, and up 745.46% sequentially from $3.0 million in Q4 2024.
NuCana (NCNA) Net Equity Issued and Repurchased (2018 - 2025) Analysis & Trends
NuCana (NCNA) has 8 years of Net Equity Issued and Repurchased data on file, last reported at $25.6 million in Q3 2025.
- For the quarter ending Q3 2025, Net Equity Issued and Repurchased rose 303.64% year-over-year to $25.6 million; the trailing twelve-month figure through Dec 2025 stood at $35.0 million (up 210.47% YoY), and the FY2025 full-year result was $26.6 million, up 138.52% from the prior year.
- Net Equity Issued and Repurchased improved to $25.6 million in Q3 2025, from $3.0 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $25.6 million in Q3 2025 to a low of -$272959.5 in Q3 2021.
- A 5-year average of $3.1 million and a median of $268355.0 in 2023 frame the typical range for Net Equity Issued and Repurchased.
- Across the five-year window, Net Equity Issued and Repurchased slumped 100.33% in 2021 and jumped 155606.65% in 2024, its largest moves.
- Tracing NCNA's Net Equity Issued and Repurchased over 5 years: stood at $266906.1 in 2021, then slumped by 99.5% to $1341.8 in 2022, then surged by 2212.41% to $31028.8 in 2023, then surged by 9653.83% to $3.0 million in 2024, then surged by 745.46% to $25.6 million in 2025.
- Business Quant data shows NCNA's Net Equity Issued and Repurchased at $25.6 million in Q3 2025, $3.0 million in Q4 2024, and $6.3 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 25.59 Mn |
| Sep 30, 2025 | 25.59 Mn |
| Dec 31, 2024 | 3.03 Mn |
| Dec 31, 2024 | 3.03 Mn |
| Sep 30, 2024 | 6.34 Mn |
| Sep 30, 2024 | 6.34 Mn |
| Mar 31, 2024 | 1.89 Mn |
| Mar 31, 2024 | 1.89 Mn |
| Dec 31, 2023 | 31,028.80 |
| Dec 31, 2023 | 31,028.80 |
| Sep 30, 2023 | 269,803.86 |
| Sep 30, 2023 | 269,803.86 |
| Jun 30, 2023 | 12,513.63 |
| Jun 30, 2023 | 12,513.63 |
| Mar 31, 2023 | 1,215.51 |
| Mar 31, 2023 | 1,215.51 |
| Mar 31, 2022 | 1,341.84 |
| Mar 31, 2022 | 1,341.84 |
| Dec 31, 2021 | 266,906.10 |
| Dec 31, 2021 | 266,906.10 |